Reagents and instruments for immunology, cell biology and molecular biology.

Biorbyt

Classical DNA polymérases for difficult templates

Classical DNA polymérases for difficult templates

Search result : 46 product found

Refine your search :

RUOCE / IVD

Unconjugated 38

Inhibitor/Antagonist/Agonist 38
Biochemicals 8

APPLY FILTERS
REINITIALIZE

Cat#

Description

Cond.

Price Bef. VAT

orb1910267-1g

QR-6401 is a CDK2 inhibitor. QR-6401 demonstrated robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.

1g

orb1910267-100mg

QR-6401 is a CDK2 inhibitor. QR-6401 demonstrated robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.

100mg

orb1910267-250mg

QR-6401 is a CDK2 inhibitor. QR-6401 demonstrated robust antitumor efficacy in an OVCAR3 ovarian cancer xenograft model via oral administration.

250mg

orb1910055-250mg

PF-06821497 (compound 23a) is a potent, selective and orally active Enhancer of Zeste Homolog 2 (EZH2) inhibitor, with a Ki value < 0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition. [[1844849-10-0]]

250mg

orb1910055-100mg

PF-06821497 (compound 23a) is a potent, selective and orally active Enhancer of Zeste Homolog 2 (EZH2) inhibitor, with a Ki value < 0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition. [[1844849-10-0]]

100mg

orb1910055-1g

PF-06821497 (compound 23a) is a potent, selective and orally active Enhancer of Zeste Homolog 2 (EZH2) inhibitor, with a Ki value < 0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition. [[1844849-10-0]]

1g

orb1910914-1g

LY3522348 is a highly selective, oral dual inhibitor of human ketohexokinase isoforms C and A (hKHK-C, hKHK-A). LY3522348 displayed a robust pharmacodynamic response in a mouse model of fructose metabolism and was advanced into clinical trials.

1g

orb1910914-250mg

LY3522348 is a highly selective, oral dual inhibitor of human ketohexokinase isoforms C and A (hKHK-C, hKHK-A). LY3522348 displayed a robust pharmacodynamic response in a mouse model of fructose metabolism and was advanced into clinical trials.

250mg

orb1910914-100mg

LY3522348 is a highly selective, oral dual inhibitor of human ketohexokinase isoforms C and A (hKHK-C, hKHK-A). LY3522348 displayed a robust pharmacodynamic response in a mouse model of fructose metabolism and was advanced into clinical trials.

100mg

orb1910725-100mg

STX-478 is an allosteric PI3Kα inhibitor that selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 provides robust efficacy while avoiding the metabolic dysfunction associated with the nonselective inhibitor alpelisib. [[2883540-92-7]]

100mg

orb1910725-1g

STX-478 is an allosteric PI3Kα inhibitor that selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 provides robust efficacy while avoiding the metabolic dysfunction associated with the nonselective inhibitor alpelisib. [[2883540-92-7]]

1g

orb1910725-250mg

STX-478 is an allosteric PI3Kα inhibitor that selectively targets prevalent PI3Kα helical- and kinase-domain mutant tumors. STX-478 provides robust efficacy while avoiding the metabolic dysfunction associated with the nonselective inhibitor alpelisib. [[2883540-92-7]]

250mg

orb1910405-100mg

BMS-986313 is a potent, selective, orally active RORγt inverse agonist with EC50 of 3.6 nM in GAL-4 reporter assay in Jurkat cell line, and 50 nM in IL-17 human whole blood assay.BMS-986313 demonstrated robust efficacy in preclinical models of psoriasis (the IMQ-induced skin lesion model and the IL-23-induced acanthosis model).

100mg

orb1910405-250mg

BMS-986313 is a potent, selective, orally active RORγt inverse agonist with EC50 of 3.6 nM in GAL-4 reporter assay in Jurkat cell line, and 50 nM in IL-17 human whole blood assay.BMS-986313 demonstrated robust efficacy in preclinical models of psoriasis (the IMQ-induced skin lesion model and the IL-23-induced acanthosis model).

250mg

orb1910405-1g

BMS-986313 is a potent, selective, orally active RORγt inverse agonist with EC50 of 3.6 nM in GAL-4 reporter assay in Jurkat cell line, and 50 nM in IL-17 human whole blood assay.BMS-986313 demonstrated robust efficacy in preclinical models of psoriasis (the IMQ-induced skin lesion model and the IL-23-induced acanthosis model).

1g

orb1910379-100mg

RK-582 is an orally efficacious spiroindolinone-based tankyrase inhibitor for the treatment of colon cancer. It exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered. [[2171388-28-4]]

100mg

orb1910379-250mg

RK-582 is an orally efficacious spiroindolinone-based tankyrase inhibitor for the treatment of colon cancer. It exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered. [[2171388-28-4]]

250mg

orb1910826-100mg

BMS-986251 is an orally active and selective RORγt inverse agonist with an EC50 of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC50 of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced models (preclinical models of psoriasis). [[2460133-35-9]]

100mg

orb1910379-1g

RK-582 is an orally efficacious spiroindolinone-based tankyrase inhibitor for the treatment of colon cancer. It exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered. [[2171388-28-4]]

1g

orb1910826-250mg

BMS-986251 is an orally active and selective RORγt inverse agonist with an EC50 of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC50 of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced models (preclinical models of psoriasis). [[2460133-35-9]]

250mg

‹

›